Back
CTO Realty Growth 10K Form
Sell
32
CTO
CTO Realty Growth
Last Price:
19.52
Seasonality Move:
2.71%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
2024-05-02 | 10Q | CTO/CTO Realty Growth Quarterly |
2023-10-26 | 10Q | CTO/CTO Realty Growth Quarterly |
2023-07-27 | 10Q | CTO/CTO Realty Growth Quarterly |
2023-04-27 | 10Q | CTO/CTO Realty Growth Quarterly |
2022-10-27 | 10Q | CTO/CTO Realty Growth Quarterly |
2022-07-28 | 10Q | CTO/CTO Realty Growth Quarterly |
Receive CTO News And Ratings
See the #1 stock for the next 7 days that we like better than CTO
CTO Financial Statistics
Sales & Book Value
Annual Sales: | $109.12M |
---|---|
Cash Flow: | $21.19M |
Price / Cash Flow: | 9.03 |
Annual Sales: | $19.88 |
Price / Book: | 0.98 |
Profitability
EPS (TTM): | 0.60000 |
---|---|
Net Income (TTM): | $20.29M |
Gross Margin: | $78.94M |
Return on Equity: | 4.08% |
Return on Assets: | 1.92% |
CTO Realty Growth Earnings Forecast
Key CTO Realty Growth Financial Ratios
- The Gross Profit Margin over the past 40 years for CTO is 72.34%.
- The Selling, General & Administrative Expenses for CTO have been equal to 13.06% of Gross Profit Margin.
- The Research & Development expenses have been 0.00% of Revenue.
- The Interest Expense is 386.78% of Operating Income.
- The Net Earning history of CTO is 5.07% of Total Revenues.
- Per Share Earnings over the last 40 years have been positive in 19 years.
CTO Realty Growth Stock Price Chart
Industry, Sector and Symbol
Stock Exchange: | NYSE |
---|---|
Industry: | Diversified REITs |
Sector: | Real Estate |
Current Symbol: | CTO |
CUSIP: | 210226 |
Website: | ctoreit.com |
Debt
Debt-to-Equity Ratio: | 0.88 |
---|---|
Current Ratio: | 8.17 |
Quick Ratio: | 8.09 |
Price-to-Earnings
Trailing P/E Ratio: | 650 |
---|---|
Forward P/E Ratio: | 0 |
CTO Technical Analysis vs Fundamental Analysis
Sell
32
CTO Realty Growth (CTO)
is a Sell
Is CTO Realty Growth a Buy or a Sell?
-
CTO Realty Growth stock is rated a Sell
The current CTO Realty Growth [CTO] share price is $19.50. The Score for CTO is 32, which is 36% below its historic median score of 50, and infers higher risk than normal.